RxDoctor Payments Data

Laura Holliger

Primary Care · North Canton, OHNPI 1437605409

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.0% of the total across 697 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 52 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,152in general payments, 2019–2025

Across 697 payments — averaging $14.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$756
  • Novo Nordisk$740
  • AstraZeneca$721
  • Boehringer Ingelheim$527
  • GSK$479
  • plus $5K from 46 others

What the payments were for

  • Food & beverage$10,05299%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,152 in reported general payments places this provider in the 95th percentile of 321 primary care providers in Ohio.

See all primary care providers in Ohio

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban148$127,896
JardianceEmpagliflozin94$92,661
OzempicSemaglutide57$77,151
FarxigaDapagliflozin Propanediol43$47,980
RybelsusSemaglutide31$44,734
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$44,446
XareltoRivaroxaban34$38,372
TrulicityDulaglutide27$26,975
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$25,452
Repatha SureclickEvolocumab22$24,691
MyrbetriqMirabegron28$21,326
MounjaroTirzepatide19$19,327
GemtesaVibegron25$18,402
JanuviaSitagliptin Phosphate15$17,256
LinzessLinaclotide27$16,529

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$756$130,873162 claims
Novo NordiskOzempic, Rybelsus$740$121,88688 claims
Boehringer IngelheimJardiance, Stiolto Respimat$527$105,673106 claims
AstraZenecaFarxiga$721$47,98043 claims
Lilly USA, LLCTrulicity, Mounjaro$449$46,30246 claims
GSKTrelegy Ellipta$479$44,44638 claims
Johnson & JohnsonXarelto$115$38,37234 claims
MerckJanuvia, Belsomra$354$23,32627 claims
Astellas Pharma US IncMyrbetriq$255$21,32628 claims
Sumitomo Pharma America, Inc.Gemtesa$43$18,40225 claims
AbbVieLinzess$1,762$16,52927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 321 primary care providers in Ohio.

Other primary care in North Canton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →